Cancer pain
Conditions
Interventions
Group ?:morphine-pregabalin combination followed by morphine-placebo
Group ?:morphine-placebo combination followed by morphine-pregabalin
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with cancer pain whose pain intensity>=4 on a 0 to 10 numerical rating scale (NRS) before analgesia treatment; pain intensity could be controlled with morphine monotherapy at a range of 0 to 3 and breakthrough pain=180mg/day; neuropathic pain diagnosis according to Douleur Neuropathique 4 questionnaire (DN4) (on a scale from 0 to 10, with higher number indicating probability of neuropathic pain), DN4>= 4[17]. In order to make sure that patients were at a stable stage of cancer during the study, their Kamofsky performance status (KPS) (on a scale from 0 to 100, with higher numbers indicating ability of living independence) must be >=40 and quality of life (QOL) (on a scale from 0 to 60, with higher numbers indicating better health-related quality of life)>30.
Exclusion criteria
Exclusion criteria: Patients who were unable to take medications orally, currently receiving oncologic treatment, unable to cooperate, plasma creatinine>1.5 mg/ml or creatinine clearance<60 ml/min, taking nonopioid analgesics and other adjuvant drugs also were excluded from the study. Patients were withdrawn from the study when a new pain due to disease progression developed or when intolerable side effects occurred during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numeric rating scale;Medical outcomes study sleep scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Constipation assessment scale;Hamilton Anxiety Scale;Hamilton Depression Scale; | — |
Countries
China
Contacts
Public ContactDou Zhi
Outcome results
None listed